Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control

Practical Diabetes

Volumn 33, Issue 4, 2016, Pages 129-132

  Curtis, Louise ^a   Humayun, Malik Asif ^a   Walker, James ^a   Hampton, Kerri ^a   Partridge, Helen ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

GLP 1 analogues; SGLT2 inhibitor; type 2 diabetes; weight loss

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; EXENDIN 4; GLICLAZIDE; GLIMIPRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PREMIX INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GLYCEMIC CONTROL; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POLYDIPSIA; RETROSPECTIVE STUDY; TREATMENT DURATION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84978062365     PISSN: 20472897     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.2018     Document Type: Article

References (18)

1. Hex N, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855–62.
2. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.
3. National Diabetes Audit 2012/2013. http://www.hqip.org.uk/assets/NCAPOP-Library/NCAPOP-2014-15/NDA-Care-Processes-report-1-Final.pdf [accessed December 2015].
4. Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79.
5. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(Suppl 2):S151–6.
6. Diabetes UK Professional Conference. March 11–13, 2015; London, UK. Abstract A6 (P143).
7. Rosenstock J, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015;38:376–83.
8. Drucker D, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–705.
9. Vilsbøll T, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
10. Aroda V. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34(6):1247–58.e22.
11. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453–67.
12. Kanai Y, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397–40.
13. Musso G, et al. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375–93.
14. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 dia-betes. BMJ Open 2012;2(5):e001007.
15. Vasilakou D, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262–74.
16. Zinman B, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28.
17. McGovern A, et al. Dapagliflozin: clinical practice compared with pre-registration trial data. Br J Diabetes Vasc Dis 2014;14(4):138–43.
18. Merovci A, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124:509–14.